Neurological Sciences

, Volume 31, Issue 4, pp 517–521 | Cite as

Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis

  • Tatiana Ribeiro
  • Maxime J. Fleury
  • Enrico Granieri
  • Massimiliano Castellazzi
  • Fernanda Martini
  • Elisa Mazzoni
  • Pierre Coursaget
  • Mauro Tognon
Brief Communication


Viral agents seem to be linked to multiple sclerosis (MS). This association is based on evidence of (1) early exposure to viruses and MS onset; (2) increased prevalence of MS disease in specific geographic regions; (3) likelihood of developing MS being more prevalent in high-risk areas; (4) altered immune responses to different viruses. In this study, sera from patients affected by MS and controls, represented by sera from patients with other neurologic diseases, both inflammatory and non-inflammatory, and from healthy donors, were investigated for the presence of antibodies against neurotropic polyomaviruses BKV, JCV and SV40 in their sera. Our study has indicated that the prevalence of BKV antibodies in sera from MS patients is higher than that detected in normal individuals, while levels of antibodies against BKV and JCV are lower in MS patients compared to those of normal subjects.


Multiple sclerosis Polyomaviruses Inflammatory diseases Non-inflammatory diseases 



This work was supported, in parts, by grants from The University of Ferrara, FAR Projects and Regione Emilia Romagna, MS project to E.G., F.M. and M.T., Fondazione Cassa di Risparmio di Ferrara to E.G., and Fondazione Cassa di Risparmio di Cento to F.M. and M.T. Italy.


  1. 1.
    Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231CrossRefPubMedGoogle Scholar
  2. 2.
    Granieri E (1997) The epidemiology study of exogenous factors in the etiology of multiple sclerosis. Introduction. Neurology 49:S2–S4Google Scholar
  3. 3.
    Bach JF (2005) Infections and autoimmune diseases. J Autoimmun 25(Suppl):74–80CrossRefPubMedGoogle Scholar
  4. 4.
    Banwell B, Krupp L, Kennedy J et al (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6:773–781CrossRefPubMedGoogle Scholar
  5. 5.
    Giovannoni G, Ebers G (2007) Multiple sclerosis: the environment and causation. Curr Opin Neurol 20:261–268CrossRefPubMedGoogle Scholar
  6. 6.
    Giovannoni G, Cutter GR, Lunemann J et al (2006) Infectious causes of multiple sclerosis. Lancet Neurol 5:887–894CrossRefPubMedGoogle Scholar
  7. 7.
    Serafini B, Rosicarelli B, Franciotta D et al (2007) Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899–2912CrossRefPubMedGoogle Scholar
  8. 8.
    Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini A, Tognon M (1998) BK and JC human polyomaviruses and simian virus 40: natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res 50:69–99CrossRefPubMedGoogle Scholar
  9. 9.
    Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M (2006) BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors. Adv Exp Med Biol 577:319–341CrossRefPubMedGoogle Scholar
  10. 10.
    Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JS, Kusne S (2002) Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis 35:1081–1087CrossRefPubMedGoogle Scholar
  11. 11.
    De Mattei M, Martini F, Corallini A et al (1995) High incidence of BK virus large-T-antigen-coding sequences in normal human tissues and tumors of different histotypes. Int J Cancer 61:756–760CrossRefPubMedGoogle Scholar
  12. 12.
    Tognon M, Corallini A, Martini F, Negrini M, Barbanti-Brodano G (2003) Oncogenic transformation by BK virus and association with human tumors. Oncogene 22:5192–5200CrossRefPubMedGoogle Scholar
  13. 13.
    Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837–846CrossRefPubMedGoogle Scholar
  14. 14.
    Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499–1504CrossRefPubMedGoogle Scholar
  15. 15.
    Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123CrossRefPubMedGoogle Scholar
  16. 16.
    Blake K, Pillay D, Knowles W, Brown DW, Griffiths PD, Taylor B (1992) JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 67:956–957CrossRefPubMedGoogle Scholar
  17. 17.
    Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437CrossRefPubMedGoogle Scholar
  18. 18.
    Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M (2004) Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 318:1–9CrossRefPubMedGoogle Scholar
  19. 19.
    Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M (2007) Simian virus 40 in humans. Infect Agent Cancer 2:13–14CrossRefPubMedGoogle Scholar
  20. 20.
    Minor P, Pipkin P, Jarzebek Z, Knowles W (2003) Studies of neutralising antibodies to SV40 in human sera. J Med Virol 70:490–495CrossRefPubMedGoogle Scholar
  21. 21.
    Butel JS, Lednicky JA (1999) Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91:119–134CrossRefPubMedGoogle Scholar
  22. 22.
    Viscidi RP, Rollison DE, Viscidi E et al (2003) Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10:278–285PubMedGoogle Scholar
  23. 23.
    Touze A, Bousarghin L, Ster C, Combita AL, Roingeard P, Coursaget P (2001) Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J Gen Virol 82:3005–3009PubMedGoogle Scholar
  24. 24.
    Newton R, Ribeiro T, Casabonne D, Alvarez E, Touze A, Key T, Coursaget P (2005) Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort. Br J Cancer 93:1305–1306CrossRefPubMedGoogle Scholar
  25. 25.
    Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA (2003) Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95:1522–1530PubMedGoogle Scholar
  26. 26.
    Engels EA, Viscidi RP, Galloway DA et al (2004) Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 96:1368–1374CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Tatiana Ribeiro
    • 1
    • 2
  • Maxime J. Fleury
    • 1
    • 2
  • Enrico Granieri
    • 3
  • Massimiliano Castellazzi
    • 3
  • Fernanda Martini
    • 4
  • Elisa Mazzoni
    • 4
  • Pierre Coursaget
    • 1
    • 2
  • Mauro Tognon
    • 4
  1. 1.Inserm U618 “Protéases et vectorisation pulmonaires”, ToursUniversity François RabelaisToursFrance
  2. 2.IFR 136 “Agents Transmissibles et Infectiologie”ToursFrance
  3. 3.Section of Neurology, Department of Medical and Surgical Sciences of Communication and BehaviourFerrara UniversityFerraraItaly
  4. 4.Section of Cell Biology and Molecular Genetics, Department of Morphology and EmbryologyUniversity of FerraraFerraraItaly

Personalised recommendations